Annita Tanini Biography and Net Worth

VP of Keros Therapeutics

Annita Tanini is the VP of Keros Therapeutics. They are 55 years old.

What is Annita Tanini's net worth?: The estimated net worth of Annita Tanini is at least $514.51 thousand as of August 18th, 2026. Tanini owns 45,144 shares of Keros Therapeutics stock worth more than $514,506 as of August 25th. This net worth evaluation does not reflect any other assets that Tanini may own. Learn More about Annita Tanini's net worth.
How do I contact Annita Tanini?: The corporate mailing address for Tanini and other Keros Therapeutics executives is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. Keros Therapeutics can also be reached via phone at 617-314-6297 and via email at [email protected]. Learn More on Annita Tanini's contact information.
Has Annita Tanini been buying or selling shares of Keros Therapeutics?: During the past quarter, Annita Tanini has sold $12,594.96 of Keros Therapeutics stock. Most recently, Annita Tanini sold 1,224 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a transaction totalling $12,594.96. Following the completion of the sale, the vice president now directly owns 45,144 shares of the company's stock, valued at $464,531.76. Learn More on Annita Tanini's trading history.
Who are Keros Therapeutics' active insiders?: Keros Therapeutics' insider roster includes Jean-Jacques Bienaimé (Director), Carl Gordon (Director), Carl Gordon (Director), Julius Knowles (Director), Jennifer Lachey (Insider), Charles Newton (Director), Keith Regnante (CFO), Alpna Seth (Director), and Annita Tanini (VP). Learn More on Keros Therapeutics' active insiders.
Are insiders buying or selling shares of Keros Therapeutics?: During the last year, Keros Therapeutics insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $21,890.00. During the last year, insiders at the sold shares 9 times. They sold a total of 10,190,363 shares worth more than $180,779,540.73. The most recent insider tranaction occured on August, 18th when VP Annita Tanini sold 1,224 shares worth more than $12,594.96. Insiders at Keros Therapeutics own 12.6% of the company. Learn More about insider trades at Keros Therapeutics.
Information on this page was last updated on 8/18/2026.

Annita Tanini Insider Trading History at Keros Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/18/2026	Sell	1,224	$10.29	$12,594.96	45,144

Annita Tanini Buying and Selling Activity at Keros Therapeutics

Keros Therapeutics Company Overview

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $11.51

$10.83

$11.66

50 Day Range

MA: $10.72

$9.97

$12.03

2 Week Range

Now: $11.51

$9.69

$22.55

Volume

70,139 shs

Average Volume

336,218 shs

Market Capitalization

$228.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99